An Open Label Study to Evaluate the Effect of Intravenous Erythropoietin on Erythropoietin Receptor Signaling and Markers for Apoptosis, Myocardial Damage and Renal Dysfunction in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Myocardial ischaemia
- Focus Therapeutic Use
- Acronyms DREAM
- 15 Feb 2013 Biomarkers information updated
- 12 Feb 2009 Planned end date changed from 1 Feb 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.
- 17 Sep 2007 New trial record.